Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers

Fibrosis Clinical Trial

— SIPHON  

Official title:

Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03308916
• Other study ID #: S-20170087
• Status: Recruiting
• Phase: N/A
• Start date: October 6, 2017
• Est. completion date: October 30, 2035

Study information

• Verified date: August 2022
• Source: Odense University Hospital
• Contact: Maja Thiele, MD, PhD, Professor
• Phone: +4524998068
• Email: maja.thiele[@]rsyd.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective screening study at Odense University Hospital to assess the effect of transient elastography and other serum and imaging markers of liver fibrosis to detect advanced fibrosis (Kleiner Fibrosis score F3-F4) in patients at risk of non-alcoholic fatty liver disease, alcoholic fatty liver disease, with a control group of participants recruited from the general population.

Description:

This protocol describes a prospective screening study at Odense University Hospital, Department of Gastroenterology and Hepatology. The investigators will use liver stiffness measurements with transient elastography to screen 3000 participants from at-risk populations and 3500 participants from the general population for advanced liver fibrosis. At-risk is defined as either (A) a prior or current alcohol overuse (≥21 units/week for men and ≥14 units/week for women) for more than 5 years, or (B) presence of the metabolic syndrome with or without concomitant type 2 diabetes mellitus. The study goal is to evaluate the aptitude of transient elastography as a screening tool for advanced liver fibrosis, based on analyses of benefit, harm, detection rate, technical applicability and prognostic potential. Secondary aims are to compare novel serum markers of liver fibrosis as potential screening tools against transient elastography: The Enhanced Liver Fibrosis test, neoepitope markers of extracellular matrix turnover, cytokeratin-18 based markers and indirect indices of fibrosis from algorithms combining routine liver blood test. Screened participants with elevated liver stiffness (≥8.0 kiloPascal; estimated 400 participants with alcoholic liver disease, 400 participants with non-alcoholic fatty liver disease and 280 participants from the general population) will be investigated with 2-dimensional shear-wave elastography and abdominal ultrasonography and a liver biopsy to confirm or reject presence of advanced fibrosis. All participants with a positive screening elastography will be invited for repeated liver stiffness measurements and serum fibrosis markers after a minimum of one year from inclusion. Participants at risk of alcoholic and non-alcoholic liver disease, independent of liver stiffness measurement at inclusion, will be invited for repeated liver stiffness measurements and serum fibrosis markers after a minimum of one year from inclusion. At-risk participants with elevated liver stiffness measurements at a follow-up visit (>6.0 kiloPascal) will be offered a liver biopsy, however no earlier than two years after the index biopsy. All participants will be followed for 10 years to assess liver-related outcomes and all-course mortality.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 6500
• Est. completion date: October 30, 2035
• Est. primary completion date: December 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 75 Years

Eligibility

INCLUSION CRITERIA

Patients are eligible for screening if the following inclusion criteria are fulfilled:

• Age 30-75 years (except the general population, which should be aged 40-75)
• Informed consent to study investigations
• Ability to read and write Danish AND (only at-risk patients)
• Prior or current alcohol overuse, defined as an average intake of =24 grams/day (14 units/week) for women and =36 grams/day (21 units/week) for men, for at least 5 years; OR
• Presence of the metabolic syndrome defined by central obesity plus any two of the following four metabolic risk factors: (a) raised triglycerides, (b) reduced HDL cholesterol, (c) raised blood pressure and (d) raised fasting plasma glucose;[38] OR
• Type 2 diabetes mellitus defined by either fasting plasma glucose =7 mmol/L, HbA1c =48 mmol/mol, a random plasma glucose =11.1 mmol/L in the presence of classic diabetes or an oral glucose tolerance test with fasting plasma glucose =7.0 mmol/L and/or 2 hour plasma glucose =11.1 mmol/L. EXCLUSION CRITERIA

We will exclude patients from screening in case of:

• Evidence of decompensated liver disease, defined by clinically obvious ascites, overt hepatic encephalopathy, jaundice or large esophageal varices with/without variceal bleeding.
• Known concurrent liver disease other than ALD and NAFLD.
• Cancer or other debilitating disease with an expected survival of less than 12 months.
• Inability to comply with the study protocol. In screened patients with liver stiffness =8 kPa we will abstain from a liver biopsy in

case of:

• Contraindications for a percutaneous liver biopsy
• Severe alcoholic hepatitis or other hepatic inflammation evidenced by transaminase elevation of more than three times the upper limit of normal.
• Hepatic congestion or bile duct dilation evidenced by ultrasound.
• Decrease of TE below 6.0 kPa from screening to time of planned liver biopsy.

Related Conditions & MeSH terms

• Fibrosis
• Liver Diseases
• Liver Diseases, Alcoholic

Intervention

Diagnostic Test:
• transient elastography
Ultrasound elastography using shear-wave elastography to measure liver stiffness as a marker of liver fibrosis. Patients with transient elastography above 8.0 kPa selected for liver biopsy to detect advanced liver fibrosis
• Enhanced liver fibrosis test
Patented, commercially available algorithm of hyaluronic acid (HA), N-terminal propeptide of collagen type 3 (P3NP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)
• Indirect serum markers of liver fibrosis
Diagnostic markers using combination of routine liver biochemistry: age, AST, ALT, platelet count, cholesterol, GGT
• Direct serum markers of liver fibrosis
Serum markers that reflect liver extracellular matrix turnover and -accumulation
• LiverTRAIL
Software that contain 199 diagnostic algorithms, containing combinations of routine tests: age, AST, albumin, alkaline phosphatase, bilirubin, GGT, INR, platelet count, cholesterol and sodium, and specialist tests: transient elastography and direct serum markers of fibrosis.
• Cytokeratin 18
Cytokeratin 18 from liver cell cytoskeleton; when cells undergo apoptosis, caspase-cleaved CK18 is released (M30), whereas full-length CK18 is realised during necrosis (M65)
• Omics markers
Markers combining signatures of liver fibrosis and hepatic inflammation from many 'omics technologies

Locations

Country	Name	City	State
Denmark	Department of Gastroenterology and Hepatology, Odense University Hospital	Odense

Sponsors (16)

Lead Sponsor

Collaborator

Maja Thiele

Biomedical Research Foundation, Academy of Athens, Esbjerg University Hospital of South-West Jutland, European Molecular Biology Laboratory, EMBL, University of Heidelberg, Horizon 2020 - European Commission, Manatee APS, Nordic Bioscience A/S, Novo Nordisk A/S, Odense Municipality Alcohol Rehabilitation Unit, Siemens Healthcare A/S, Steno Diabetes Center Copenhagen, Svendborg Municipality Alcohol Rehabilitation Unit, University of Copenhagen, University of Oslo, University of Southern Denmark, VLV Bio, Peviva AB

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Biopsy-verified advanced fibrosis	Number of patients with biopsy-verified, advanced fibrosis (Kleiner fibrosis score =F3) detected by screening	5 years
Primary	Liver-related outcomes	Number of liver-related clinical outcomes during 10 years of follow up after the first screened patient, compared to a matched, historical control group (The Inter99 study and the Copenhagen and Odense alcohol rehabilitation cohorts). Liver-related outcomes are defined as liver-related death, liver transplant, progression to liver-related complications (ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, jaundice, bleeding from esophagastric varices, hepatocellular carcinoma) or MELD-Na score >15	10 years
Secondary	Liver related outcomes	Number of liver-related clinical outcomes during 10 years of follow up after the first screened patient, compared to a matched, historical control group (The Inter99 study and the Copenhagen and Odense alcohol rehabilitation cohorts). Liver-related outcomes are defined as liver-related death, liver transplant, progression to liver-related complications (ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, jaundice, bleeding from esophagastric varices, hepatocellular carcinoma) or MELD-Na score >15	10 years
Secondary	Mortality	Overall number of deaths during 10 years of follow up after the first screened patient, compared to a matched, historical control group (The Inter99 study and the Copenhagen and Odense alcohol rehabilitation cohorts).	10 years